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Abstract: Intervertebral disc (IVD) degeneration is a major risk factor of low back pain. It is defined 
by a progressive loss of the IVD structure and functionality, leading to severe impairments with 
restricted treatment options due to the highly demanding mechanical exposure of the IVD. Degen-
erative changes in the IVD usually increase with age but at an accelerated rate in some individuals. 
To understand the initiation and progression of this disease, it is crucial to identify key top-down 
and bottom-up regulations’ processes, across the cell, tissue, and organ levels, in health and disease. 
Owing to unremitting investigation of experimental research, the comprehension of detailed cell 
signaling pathways and their effect on matrix turnover significantly rose. Likewise, in silico research 
substantially contributed to a holistic understanding of spatiotemporal effects and complex, multi-
factorial interactions within the IVD. Together with important achievements in the research of bio-
materials, manifold promising approaches for regenerative treatment options were presented over 
the last years. This review provides an integrative analysis of the current knowledge about (1) the 
multiscale function and regulation of the IVD in health and disease, (2) the possible regenerative 
strategies, and (3) the in silico models that shall eventually support the development of advanced 
therapies. 
Keywords: intervertebral disc; extracellular matrix; disc cell molecular biology; multifactorial cell 
stimulation; intervertebral disc degeneration; regenerative medicine; multiscale modeling;  
computational multiphysics; computational systems biology 
 
1. Introduction 
The intervertebral disc (IVD) is a major mechanical load-bearing organ and is respon-
sible for the functional articulation of the spine. It is composed of three tissues: the nucleus 
pulposus (NP), the annulus fibrosus (AF), and the cartilage endplate (CEP) that strongly 
Citation: Baumgartner, L.;  
Wuertz-Kozak, K.; Le Maitre, C.L.; 
Wignall, F.; Richardson, S.M.;  
Hoyland, J.; Ruiz Wills, C.;  
González Ballester, M.A.; Neidlin, 
M.; Alexopoulos, L.G.; et al.  
Multiscale Regulation of the  
Intervertebral Disc: Achievements  
in Experimental, in Silico and  
Regenerative Research.  
Int. J. Mol. Sci. 2021, 22, 703. 
https://doi.org/10.3390/ijms22020703 
Received: 25 November 2020 
Accepted: 24 December 2020 
Published: 12 January 2021 
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional 
claims in published maps and insti-
tutional affiliations. 
 
Copyright: © 2021 by the authors. 
Licensee MDPI, Basel, Switzerland. 
This article is an open access article 
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (http://cre-
ativecommons.org/licenses/by/4.0/). 
Int. J. Mol. Sci. 2021, 22, 703 2 of 42 
 
 
interact among each other. These interactions depend on the composition and ultrastruc-
ture of each tissue that are largely regulated by the response of the disc cells to microen-
vironmental biological, chemical, and physical cues, transmitted to the cells through the 
extracellular matrix (ECM). A balance between anabolic and catabolic processes on a cel-
lular level, i.e., tissue homeostasis, is essential for a healthy turnover of the ECM compo-
nents and optimal aging [1–4]. In contrast, the perturbation of this equilibrium might 
cause IVD degeneration (DD), with elevated catabolic activity leading to disease progres-
sion [1,5–7]. 
The first morphological signs of DD might appear already during adolescence and 
largely progress toward moderate to advanced degeneration within the three next dec-
ades of life [8]. Such progression is manifest in MRI images [9], visible though a general 
reduction of the disc height; a shift of image signal in the NP toward inhomogeneous, 
gray or black shaded nuances that reflect dehydration and cracks; a loss of distinction 
between the NP and AF regions; and possible endplate defects and disc bulging or herni-
ation [9–11]. It is commonly believed that these changes start with a drop of pressure 
within the NP because of dehydration. 
On the one hand, the drop of intradiscal pressure makes the axial deformation of the 
disc increase under the action of external mechanical loads, which eventually favors the 
collapse of the AF structure. The AF lamellae become unorganized, fissured, and used to 
bulge within the NP and/or outward [12]. On the other hand, water loss is commonly 
interpreted as a consequence of proteoglycan (PG) depletion [2]. Interestingly, theoretical 
simulations associated the loss of PG and tissue swelling with the propagation of radial 
crack formation [13], leading to radiating annular tears [14], which might end up in IVD 
herniation. 
Though appealing, such a systematic explanation of DD progression explains only a 
subset of herniated IVD phenotypes [15], i.e. the AF-driven phenotype of DD. Even 
though, the spatiotemporal emergence of several subsets of phenotypes related to differ-
ent types of AF tears [14,16] remains difficult to explain. Furthermore, endplate-driven 
DD is also recognized as a source of important disc disease phenotypes [17]. Signs of in-
flammation around the endplate, called Modic changes, are often visible [18] and have 
been associated with DD [19], with endplate defects and with severe low back pain (LBP) 
[20,21]. Yet, the associated pathophysiology remains largely unexplained. Interestingly, 
the understanding of IVD-related diseases differs between authors, which led to an at-
tempt to standardize the nomenclature about normal and pathological lumbar disc by the 
“Combined Task Forces of the North American Spine Society” [22]. In any case, degener-
ative disc changes at the tissue level alter the mechanics of the entire IVD [12] and account 
for at least 40% of all LBP cases [23,24]. 
The IVD architecture provides the non-degenerated IVD with adequate resistance to 
traumatic loading, as seen in sport or traffic accidents, such that isolated, traumatic IVD 
ruptures are hardly seen [25]. Disc rupture is, therefore, widely accepted to be a slow pro-
cess, consisting of an accumulation of micro injuries under rather physiological loads, 
promoted by intricate biochemical and mechanobiological processes that end up in debil-
itated tissues. Considerable progress has been made over the past 20 years identifying risk 
factors for DD, and the condition, long thought to be secondary to occupational loading, 
has also been shown to be highly heritable [26,27]. Yet, heredity was confirmed to be sig-
nificant (55%) for a reduced number of phenotypes such as endplate defects [20] and ex-
plains less than 50% of the progression of DD in the lower lumbar spine [26] where me-
chanical loads are the highest. More recently, greater understanding of the interplay be-
tween genes, cellular behavior, and mechanobiology has been achieved [28], and a causal 
link has been proposed between IVD pathology and the expression of cytokines and of 
structural protein proteases from resident cells [29–33]. 
The understanding of the multiple interplays within the IVD is further challenged by 
the need to consider the delicate nutritional balance to ensure cell survival and activity 
[34] in what is the largest avascular organ of the human body. Controlling inflammation, 
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nutrition, mechanical deformations, and the interactions thereof appears cornerstone, 
therefore, to understand where to act, to slow down, stop, or reverse DD through molec-
ular or cellular therapies or biomaterial-based strategies. Current literature provides a 
wealth of information about the response of IVD cells to inflammatory, nutritional, and 
mechanical isolated stimuli. Yet, such knowledge is not sufficient to apprehend and con-
trol the complex combination of factors that effectively shape the microenvironment of 
disc cells in situ. The comprehensive understanding of the emergence and net effect of 
multiple combinations of cell stimulators is difficult to achieve through experimental 
and/or clinical observations. Fortunately, computational implementations of theoretical 
mechanical, multiphysics, and biology models are constantly growing, and simulations 
reveal unsuspected capacity to reasonably predict multifactorial tissue or ECM regulation 
at different scales [35,36] or specific degeneration paths [37]. 
Accordingly, this review aimed to provide an overview of the latest findings about 
the IVD function and regulation in health and disease at the tissue, cell, and molecular 
levels; about progresses in IVD regenerative medicine; and about in silico research for 
knowledge integration and discovery over different time and length scales. 
2. IVD Extracellular Matrix in Health and Disease 
The biochemistry and the ultrastructure of the intervertebral disc ECM regulate the 
physical interactions among the disc tissues, i.e., the CEP, the AF, and the NP, and provide 
the IVD with unique mechanical functions [38,39]. The main ECM components of the IVD 
tissues are water, collagen (types I and II), and PG, and the relative contents and organi-
zation of these components are finely tuned in each disc tissue (Figure 1) [38,40]. 
The solid matrix of the NP mostly contains PG and non-oriented collagen type II, 
while the CEP contains PG and highly oriented collagen type II [41]. The AF is made of 
concentric bundles of collagen types I and II. While collagen type I is predominant, the 
relative amounts of collagen type II increase from the outer AF to the inner AF, adjacent 
to the NP [42]. PG is present in the interlamellar space, along with small amounts of elastic 
fibers and other types of fibrils [43]. It has been demonstrated that the turnover rate of 
collagen and aggrecan in the IVD is relatively slow due to long half-lives, i.e., around 95 
and 12 years, respectively [44,45]. 
 
Figure 1. Biochemical composition of disc tissues ([46], adapted from [47]). 
Interestingly, collagen turnover rate decreases with age, along with increased syn-
thesis of types I and III collagen [3], whereas the turnover rate of aggrecan increases, the 
result being a gradual progression of a more fibrotic and less hydrated tissue with increas-
ing age. In the following subsections, the current knowledge about the main ECM com-
ponents’ PG, collagens, and water is summarized. 
2.1. Proteoglycans 
Aggrecan is the principal PG inside the IVD. Glycosaminoglycan (GAG) chains are 
attached to the main core protein of the PG, and they contain negatively charged sul-
phated groups [48]. The size and aggregation of PG molecules impedes these negative 
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charges to move spatially and, because tissue electro-neutrality needs to be respected, 
small counter-ions, e.g., potassium and sodium, are attracted from the interstitial fluid, 
generating a gradient of chemical potentials between the regions respectively internal and 
external to the disc. Such a gradient can only be reduced through the entrance of water in 
the IVD, known as Donnan osmosis. The tissues swell and the collagen fibers become 
tensed, leading to an intradiscal osmotic pressure. Osmotic pressurization and IVD hy-
dration are crucial for the basal hydration of the NP and the functional biomechanics of 
the IVD. 
With age or degeneration, the total content of PG decreases in all disc tissues [49,50], 
and increased amounts of small non-aggregating PG are found [49,51]. In the NP, the drop 
of PG content and non-aggregating PG negatively affect the osmotic potential and the 
capacity of the tissue to attract water. Whether the loss of PG affects the mechanical sta-
bility of the IVD at the macroscopic level remains unclear [52], but theoretical approaches 
suggest that it favors the initiation and propagation of radial cracks through the IVD [13], 
as observed in IVD specimens [14]. Furthermore, the accumulation of non-aggregating PG 
might favor the transport of small glycans out of the disc during daily load cycles [41], 
and IVD glycoprofiles might be a hallmark of DD [53]. High-weight hyaluronan-based 
molecules were pointed out as potential protectors against DD [54], whereas hyaluronic 
acid fragments would increase the expression of key inflammatory cytokines by IVD cells 
[55]. Interestingly, during normal aging the IVD shows less than 1% height loss per year, 
whereas degenerating discs loose approximately 3% height per year [17]. 
In the AF, PG is mostly present in interlamellar spaces. On the one hand, these inter-
lamellar spaces have been identified as the preferred path for the extrusion of nuclear 
material [56]. On the other hand, single nucleotide polymorphism associated to the aggre-
canase ADAMTS 5 has been significantly associated with AF tears in DD [57], suggesting 
a relevant implication of interlamellar PG in the IVD pathophysiology. In the CEP, the 
control of the mobility of molecules by PG probably ensures key protection against the 
loss of structural proteins and water through the bony endplates [58]. While PG depletion 
with age or DD might explain the increased permeability of the CEP measured with aging 
[59], in silico models suggest that the fine-tuning of PG contents within the CEP is actually 
important to avoid critical chronic dehydration of the IVD under daily mechanical loads 
[37]. 
2.2. Collagen 
Collagen types II and I are the major structural component of the IVD. Type I collagen 
forms highly oriented concentric lamella within the AF, which provides the AF with re-
sistance to multiaxial loads and finely tunes the mechanical strength of the disc. Collagen 
type II forms a loose network, especially within the NP, and it is more extensible than 
collagen type I [60,61]. 
In the NP, the flexibility of collagen type II network allows the swelling of the PG 
through Donnan osmosis, whereas the elastic response of the stretching fibers generates 
tissue turgidity, providing the IVD with strength under high pressurization and relative 
flexibility otherwise. The first oriented collagen bundles appear oriented in the transition 
zone between the NP and the AF and the proportion of collagen type I to collagen type II 
increases toward the outer AF [42]. The presence of collagen type II would limit the lateral 
aggregation of collagen type I fibrils and leads to matrices of increased porosity [62], 
which fosters proper hydration of the inner IVD and the transport of molecules to disc 
cells. At the same time, the increasing amount of collagen type I toward the outer AF in-
creases the effective resistance to fluid flow, favoring hydrostatic pressures and proper 
cell phenotypes in the inner AF [63]. The CEP matrix has predominantly collagen type II 
fibers. While it needs to allow the transport of important solutes between the disc and the 
bone marrow [64], its hydraulic permeability, of the order of 1.10−14 m4/Ns [65], is one or-
der of magnitude lower than the radial permeability of the AF [66]. Interestingly, piezoe-
lectric potentials associated with the disc collagen fibers have been measured and were 
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suggested to be one of the triggers of functional cell alignments, especially in the AF [67]. 
In general, it is clear that the functional distribution of collagen types I and II throughout 
the IVD supports multiple important functions. 
With degeneration or aging, the relative amount of collagen type I increases in the 
NP [8], which in addition to PG depletion would also explain the dehydration of the IVD, 
i.e., reductions of tissue porosities [68], in general. Decreased tissue porosity due to mod-
ified balance between collagen types I and II would explain why water and PG contents 
only moderately correlate to each other [69]. Collagen cross-links are also important; 
within the normal NP, high concentrations of pyridonoline cross-links are found, but with 
degeneration these cross links are replaced with the pentosidine cross-links [70,71], which 
increase the susceptibility of the tissue to tears [71,72]. 
Other collagens such as types III, V, VI, IX, and XI make up around 20% of the total 
collagen components of the disc and are thought to be involved in the organization of the 
collagen fibrils [73] and to play a key role in the functional mechanical behavior of the 
complex AF interlamellar regions [43]. Remarkably, type VI collagen is an important pe-
ricellular molecule [74] thought to be essential for the mechanosensing of IVD cells [75–
77]. 
2.3. Water 
As discussed in Sections 2.1 and 2.2, the function of the IVD tissue matrices cannot 
be dissociated from the very specific interactions of the ECM components with interstitial 
water. Remarkably, the physics of water in the IVD and the macroscopic effect thereof 
depend on the balance of PG and collagen contents. While PG controls Donnan osmosis, 
it might further affect the shear stiffness of cartilage-like tissues [78]. Multi-physics models 
and experiments also suggest that the effective turgidity of disc tissues is additionally 
controlled by the existence of a dual porosity, generated by volumes of exclusion of PG 
molecules generated by the fibrillar matrix [79,80]. 
3. IVD Cell Activity and Molecular Biology in Health and Disease 
The cells responsible for disc maintenance represent only 1% of the volume of the 
organ [81], the disc cell densities (~4 × 103 cells/mm3 in the NP; ~9 × 103 cells/mm3 in the 
AF; ~15 × 103 cells/mm3 in the CEP) being among the lowest within the body, due to the 
low nutrient supply [82]. These densities decrease with aging and DD [82–84]. The cells 
of the CEP are chondrocytes [82], while those in the outer AF are similar to fibroblasts. 
The NP cells of a mature human disc are spherical and, while similar to chondrocytes [85], 
they synthesize a greater proportion of PG than chondrocytes, with a PG-to-collagens ra-
tio of about 27:1 [86], and have a number of distinctive cell markers [87,88]. Mature NP 
cells are uniquely derived from notochordal cells, which, in humans, are lost during ado-
lescence [89–91]. From one IVD tissue to another, cells display transitional phenotypes, 
illustrating the likely influence of their microenvironment on their phenotype and activity 
[63]. 
3.1. Multifactorial Regulation of Cell Activity in Health 
The IVD has low nutritional supply with blood vessels located in the vertebral end-
plates and outer AF [82]. This leads to a hostile environment for cells, characterized by 
low oxygen tension, low glucose concentrations, high lactate levels, i.e. low pH, and high 
osmolality, altogether under the action of dynamic loads [92–97]. However, the cells of 
the IVD are remarkably adapted to such conditions [98]. 
In hypoxia, the increased production of lactate generated during adenosine triphos-
phate synthesis decreases the pH. Accordingly, IVD cells express a number of control 
mechanisms that maintain pH homeostasis, such as expression of plasma membrane mon-
ocarboxylate transporters [99] and bicarbonate recycling mechanisms [100]. NP cells fur-
ther show robust and constitutive hypoxia inducible factor (HIF) 1 expression, and under 
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hypoxic conditions the inducible subunit of HIF-1, HIF-1α, accumulates due to the inhi-
bition of prolyl hydroxylase enzymes. Then, it translocates to the nucleus, where it binds 
to the constitutively expressed subunit HIF-1β. Subsequent binding of this dimer to hy-
poxia response elements on the promoter region of target genes allows the regulation of 
gene expression [101]. HIF-1α has been shown to contribute to the survival of NP cells in 
the harsh, hypoxic environment by increasing gal-3 expression, thereby inhibiting Fas re-
ceptor/Fas ligand-mediated apoptosis [102]. It may also be involved in hypoxia-driven 
suppression of NP cells’ autophagy via inactivation of the mTOR (mammalian target of 
rapamycin) signaling pathway [103]. Furthermore, HIF-1 seems to play a crucial role in 
supporting adequate energy metabolism (i.e., anaerobic glycolysis) in NP cells by regulat-
ing the expression of the glucose transporters GLUT-1, GLUT-3, and GLUT-9 [104]. The 
crucial role of HIF-1α in NP homeostasis has been underlined by knockout experiment in 
mice, whereby HIF-1α deficiency resulted in DD, as evidenced by reduced PG and colla-
gen II contents [105]. Interestingly, research in other areas points toward cross talk be-
tween the nuclear factor kappa B (NF-κB) and HIF-1 signaling pathways [106], which 
could constitute a molecular link between hypoxia and inflammation. First data in NP 
cells support this notion as prolyl hydroxylase domain-containing protein 2, able to de-
grade HIF-1α [107], was shown to co-activate NF-κB signaling (Section 4.1) [108]. 
ECM osmolarity fluctuates (~430 to 496 mOsm ) with normal daily activity in the IVD 
[109,110] and disc cells are well adapted to respond to these fluctuations [111,112] through 
robust expression of osmosensitive transcription factor TonEBP (tonicity-responsive en-
hancer binding protein) ,which maintains cellular function under daily osmotic changes 
[113,114]. TonEBP (or NFAT5, nuclear factor of activated T-cells 5, or OREBP, osmotic 
response element-binding protein) is a transcription factor modulated by growth factors 
(GF) [115], cytokines [115,116], and calcium [117]. It is involved also in the survival of NP 
cells in the hyperosmotic milieu [118]. Together with other osmosensitive pathways and 
receptors, especially from the mitogen-activated protein kinases (MAPK), transient recep-
tor potential (TRP) channel and Aquaporin family, TonEBP/NFAT5 (tonicity-responsive 
enhancer binding protein/nuclear factor of activated T-cells 5) plays a crucial role in cell 
volume regulatory mechanisms [118]. In rat NP cells, extracellular signal-regulated kinase 
(ERK) phosphorylation following hyperosmotic stress results in TonEBP/NFAT5 activa-
tion, thereby promoting cell survival [114,119]. The tight cross talk between ERK and 
TonEBP/NFAT5 and the link to cell survival/apoptosis have also been demonstrated 
through pharmacological ERK inhibition [119–121]. In addition to MAPK, 
TonEBP/NFAT5 interconnects to the NF-kB pathway [122,123] and interacts with mem-
bers of the TRP family [118]. The TRPV subfamily (especially TRPV4) has been identified 
as potential osmo- and volume-sensors involved in regulatory volume change mecha-
nisms and cell signaling, following osmotically driven opening of the channel pore and 
subsequent influx of extracellular Ca2+ [118]. Consequently, TonEBP/NFAT5 has a wide 
variety of target genes, ranging from organic osmolytes [124] and aquaporins [125] to 
ECM molecules [114] and pro-inflammatory cytokines [116]. In particular, aquaporins 
form transmembrane water channels and are able to regulate intra- and extracellular wa-
ter balance, which is essential to keep cells alive in fluctuating osmotic environments [125–
129]. 
The IVD is constantly subjected to dynamic loads and the cells embedded within the 
ECM experience compressive, tensile, and shear mechanical stresses and strains [130]. 
They respond to these loads via a number of mechanotransduction mechanisms, which 
have been reviewed previously [130–132]. For example, TRP channels, whereby TRPV4 as 
well as TRPC6, TRPM2, and TRPML1 stand out due to fundamental roles in osmo- and 
mechano-sensing [118,133,134]. NP cells are more responsive to hydrostatic pressure, 
while AF cells respond better to cyclic strain [135]. Mechanical loads considered physio-
logical for non-degenerative IVD cells promote matrix synthesis, while higher loading re-
gimes can promote catabolism and contribute to DD [130–132]. IVD cells activate distinc-
tive signaling pathways depending on the load magnitude, frequency, and duration, in a 
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zone-specific manner [136–138]. Over the past years, the YAP/TAZ signaling has also 
come into focus in mechanobiology due to its regulation by the mechanical signals elicited 
by the surrounding ECM [139,140], whereby integrins in focal adhesions (FA) evidently 
play a crucial role [141]. YAP and TAZ are transcriptional coactivators with involvement 
in development, tissue homeostasis, tissue renewal/regeneration, and cell proliferation 
and survival to stress [139]. Previous research clearly indicated that cell stretching over 
the ECM with reformation of the cytoskeleton causes YAP/TAZ activation, whereas re-
striction of cell adhesion inhibits YAP/TAZ-related transcription [142]. Such responses 
were observed when NP cells were cultured in laminin-functionalized polyethylene gly-
col (PEG) hydrogels with different stiffnesses [143]. In AF cells, the degree of fiber align-
ment and fiber stress was shown to affect YAP/TAZ activation, with lower nuclear 
YAP/TAZ in the case of fiber alignment and prestress (highly elongated cell morphology 
and lower FA area). In contrast, slack and random fibers promoted larger FA and nuclear 
YAP/TAZ localization [144]. YAP inhibition seems to occur by cell-to-cell contact in IVD 
cells [145]. Remarkably, while the expression of YAP decreases with age [146], YAP silenc-
ing was shown to promote NP cell senescence [145], which adds to the difficulty to duly 
apprehend the variation of disc cell regulation, upon multifactorial simulation and aging. 
IVD cell activity is finely related with careful balance of multifactorial cell cues. Al-
tered balance might result in a vicious cycle of catabolic cell responses and functions [147], 
which leads to a loss of functional sensitivity to, e.g., mechanical loads at a cellular level, 
to undue osmolarity, and to ECM depletion over time at a tissue level, which finally re-
sults in DD [148,149]. 
3.2. Multifactorial Regulation of Cell Activity in Disease 
During DD, cellular changes lead to increased production of catabolic cytokines 
[29,30,150–155], matrix-degrading enzymes [4,156–162], and neurotropic and angiogenic 
factors [163–177], which lead to ECM degradation, catabolism, and nerve and blood vessel 
ingrowth [178–186] (Figure 2). 
 
Figure 2. Cellular regulation of the intervertebral disc under degenerated and non-degenerated conditions. 
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Furthermore, the number of functional cells decreases with increases in apoptosis, 
autophagy [187], and cellular senescence [147,188–195]. The initiating trigger of these cat-
abolic events is clearly multifactorial, and different processes are likely to predominate in 
individual patients, with links to genetics, abnormal loading profiles, infection, and dia-
betes, among other potential risk factors [196–198]. 
For example, cells from a degenerative IVD respond differently to mechanical stimuli 
with mechanotransduction pathways altered during degeneration, which further leads to 
decreased synthesis and increased degradation of the ECM [75,137,199–201]. IVD cells re-
spond to altered biomechanics, infection, or metabolic changes with increased production 
of catabolic cytokines, leading to the generation of a ‘cytokine soup’ regulated predomi-
nantly by the pleiotropic cytokine interleukin (IL)-1 [154,202]. The IVD environment be-
comes progressively more hostile for cells with decreased IVD hydration and nutritional 
supply, leading to increased lactate production, decrease of pH, and decreased osmolarity 
[93]. Cells become less able to withstand these conditions and lose the physiological re-
sponse mechanisms that would maintain homeostasis [116,118,126,203,204]. Low glucose 
[159,205–207] and high lactate concentrations [159,205,207,208] lead to a higher rate of cell 
death and a catabolic shift in mRNA expression. However, the role of oxygen remains 
controversial. While it seems that NP cells survive well with limited oxygen levels 
[159,207], on the one hand, the lack of oxygen has been alternatively linked to either lower 
[207] or unmodified [209] GAG synthesis by NP or AF cells. On the other hand, a signifi-
cant rise in aggrecan mRNA expression at 1%, compared to 6% or 21% oxygen concentra-
tions, was found, while mRNA expression for collagen type II was decreased [159]. Other 
studies report increases in both collagen type II and aggrecan at 1% oxygen [209]. 
Cell senescence has been reported to be a contributing factor toward the progression 
of DD, and the causes and molecular mechanisms that are seen to take place were already 
nicely reviewed [191]. A correlation between age and increased measures of senescence 
has been shown as well as associations between senescence and elevated MMP and 
ADAMTS expression [193,210]. As well as losing replicative ability, senescent cells also 
release pro-inflammatory cytokines and matrix-degrading enzymes. This cell characteris-
tic is referred to as senescence-associated secretory phenotype (SASP) [191]. Secretion of 
pro-inflammatory cytokines by senescent disc cells includes various catabolic factors, in-
cluding tumor necrosis factor α (TNF-α) and IL-1β [30]. 
Apoptosis and autophagy are other important aspects of cell activity in the IVD. The 
mechanisms of action and roles in matrix homeostasis and degeneration have been re-
viewed and discussed in detail [187,211,212]. It has been observed in human, animal, and 
in vitro studies that excessive NP and AF cell apoptosis and autophagy takes place during 
DD, which may be exacerbated by harsh disc cell microenvironments [187,213]. Autoph-
agy is also important in natural cell and protein turnover within the IVD as low levels 
have been reported in non-degenerate rat NP and AF cells [214]. However, its role during 
DD is more complicated, as both higher [215,216] and lower [217] levels of autophagy 
have been shown. The potentially conflicting roles of autophagy during DD is reviewed 
and discussed elsewhere [218]. In regards to the role of cytokines, IL-1β has been shown 
to induce both autophagy and apoptosis in rat AF cells, but only in serum-deprived con-
ditions [219,220], which may be a more reflective condition of the IVD, where nutrient 
levels are low due to avascularity. 
Cell survival and cell death under multifactorial cell environments are strongly con-
trolled though mTOR and Notch cell signaling pathways. mTOR is downstream of 
PI3/Akt, whereby mTOR is substrate of Akt [221]. Akt can induce direct and indirect acti-
vation of mTOR and, similar to PI3/Akt, the protein kinase mTOR has a central role in cell 
metabolism, growth, proliferation, and survival [222]. Increasing evidence highlights that 
mTOR controls the decision between cell survival and cell death in case of endoplasmic 
reticulum (ER) stress [223,224]. In the IVD, mTOR has mostly been investigated in the 
context of autophagy [187], i.e. an intracellular process that allows cells to remove mis-
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folded or aggregated proteins and eliminate damaged organelles occurring due to stress-
ors such as nutrient deprivation [103,225], oxidative stress [226,227], or overloading [226], 
thus ensuring cell survival and appropriate cell metabolism [228]. On the one hand, inhi-
bition of mTORC1 promoted rabbit AF and human NP cell survival and reduced catabolic 
responses under serum and nutrient deprivation as well as by IL-1β treatment via autoph-
agy induction [225,229,230]. Furthermore, the beneficial effect of osteogenic protein 1 
treatment on rat NP cell survival under hyperosmotic culture conditions was associated 
with mTOR (and PI3/Akt) activation [231]. Interestingly, mTOR inhibition has also been 
found to affect matrix synthesis and degradation in the IVD in mice, with reduced aggre-
canolysis (likely via reduction in cell senescence) but simultaneous suppression of PG syn-
thesis, thus not leading to any changes in total PG content [232]. 
The Notch signaling pathway is a highly conserved pathway with a wide variety of 
functions in development, tissue homeostasis and diseases, ranging from stimulation of 
tissue growth to promotion of cell death under different cell microenvironments [233]. As 
transmembrane receptors with a direct route from the membrane to the nucleus, Notch 1-
4 can only exhibit such diverse functionality by a range of regulatory mechanisms such as 
tissue topology, ligand expression patterns, expression of certain enzymes, or the extent 
of cell–cell contact [234]. In IVD cells, the expression of Notch 2 is increased during DD 
[235], whereas intradiscal injection of JAG2 (which induces Notch 2) reduced DD pro-
cesses in rats [236]. Notch signaling in the IVD was activated by hypoxia [237] and pro-
inflammatory cytokine exposure [235], thereby activating NP and AF cell proliferation 
[236,237], inhibiting NP cell apoptosis promoted by TNF-α [236] and modulating the ex-
pression of anabolic and catabolic genes [238]. Yet, these effects seem to be zone-depend-
ent, with Notch activation causing catabolic and anabolic responses in AF and NP cells, 
respectively [238]. Importantly, cross talk between the Notch signaling pathway and 
MAPK, NF-kB, PI3K/Akt, and Wnt/β-catenin (Section 4.1) seems to exist [235,236]. Despite 
these fascinating findings, relatively little research has thus far been conducted on the 
Notch pathway in the IVD. 
4. IVD Regeneration Strategies: Biological Targets and Biomaterials 
Given the high incidence of DD and the related high financial burden [47] and global 
disability [239], IVD regeneration is a crucial focus in IVD research. Apart from conserva-
tive approaches, regeneration due to a manipulation of biological targets, cell therapy-
based strategies, biomaterials, and nanotechnologies to, for example assimilate the archi-
tecture of biomaterials to the native tissue or to optimize drug delivery, is currently under 
investigation. The following subsections provide an overview of the current hopes in IVD 
regeneration strategies. 
4.1. Signaling Pathways and Biological Targets 
As illustrated in the previous sections, the multifactorial regulation of IVD cell activ-
ity by cues such as mechanical loading, osmolarity, glucose, hypoxia, and paracrine and 
autocrine factors results in complex cell signaling processes that are often interconnected. 
Understanding the regulation and interconnectivity of various pathways is crucial for elu-
cidating the complex mechanisms of DD, especially when the goal is to develop novel 
molecular treatment options. 
Over the past years, the IVD research community has identified numerous promising 
biological targets. Modulating these targets, e.g., pharmacologically or through genome 
engineering approaches such as CRISPR/Cas [240], may allow interfering with the molec-
ular and biological mechanisms of DD and/or pain development. Consequently, the hope 
is to develop more effective and less invasive treatment options compared to currently 
available strategies in patient care. Some of the most promising therapeutic targets are, 
for example, MAPK, NF-κB, Wnt/β-Catenin, and PI3/Akt. 
MAPK are a family of highly conserved signal transduction pathways that facilitate 
mammalian cell responses to numerous extracellular signals. MAPK activation occurs as 
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a cascade, whereby each member of the family of MAPK is activated by specific upstream 
kinases (MAPKK), which are in turn activated by a MAPKK kinase (MAPKKK), all by 
phosphorylation [185]. In mammals, three major subfamilies of MAPK exist: ERK, the c-
Jun NH2 terminal kinases (JNK), and the p38 isoforms (p38 MAPK) [186,187]. MAPK can 
be activated by numerous cell stimuli present in the IVD and have thus been discussed as 
potential therapeutic targets in DD [241]. 
 ERK activation typically occurs via mitogens and GF (e.g., platelet-derived growth 
factor (PDGF), transforming growth factors β1 and β3 (TGF-β1, TGF-β3), fibroblast 
growth factor (FGF), and insulin-like growth factor (IGF) I [242–244]), thereby con-
trolling growth, differentiation, cell cycle progression, and development. In addition, 
ERK activation in the IVD supports cell survival following hypoxia and osmotic 
stress, the latter with cross talk to TonEBP [118–121,245–247]. Interestingly, NP-de-
rived mesenchymal stromal cells (MSC) also respond to osmotic stimuli, whereby 
hyperosmotic stress was associated with ERK activation, leading to a reduction in 
proliferation and chondrogenic differentiation [248]. Interestingly, excessive cyclic 
stretch was shown to induce AF apoptosis via inhibition of ERK phosphorylation, 
whereby β1 integrin could inhibit the apoptotic processes [249]. Pro-inflammatory 
cytokines, such as TNF-α and IL-1β, as well as stimuli known to induce inflamma-
tion, such as ECM fragments, activate the ERK pathway in IVD cells, possibly medi-
ating loss of tissue ECM proteins associated with DD [31,55,250–253], inflammatory 
and catabolic responses [250,254,255], apoptosis [256], and senescence [257]. Interest-
ingly, ERK was suppressed by stimulation with the anti-inflammatory cytokine IL-
10 [254]. Overall, these findings indicate that modulating ERK activity for therapeutic 
means is possible yet challenging due to the multifactorial role of this signaling path-
way. 
 The p38 signaling pathway is generally activated by stressors and is known to regu-
late inflammation, autophagy, apoptosis, and differentiation [241]. Numerous stud-
ies have investigated p38 in the IVD, thereby identifying hypoxia [245], hyperosmo-
larity [120], hyperphysiological mechanical loads [133], ER stress [258], acidity [257], 
high glucose levels [256], and IL-1 [253] as potent activators. Interestingly, p38 is con-
nected to TPRV4 [133], which has previously been described to transduce mechani-
cal, inflammatory, and pain signals in cartilage [259]. Different research fields have 
shown extensive cross talk between p38 and other signaling pathways, e.g., ERK 
[258], TGF-β/Smad, [260] or Akt [261], which should be investigated in IVD cells. 
Overall, inhibition of p38 is being discussed for therapeutic approaches, potentially 
reducing inflammation, pain, and disc matrix catabolism [253,262], although ultimate 
outcomes may be difficult to predict due to the extensive cross talk with other path-
ways. 
 JNK, similar to p38, is activated by stressors, GF, and pro-inflammatory cytokines 
[241,253]. Stressors entail high glucose levels [256], hyperosmolarity [120,263], TNF-
α and IL-1β exposure [250,251,255], syndecan-4 overexpression [264], and Propioni-
bacterium acnes (P. acnes) infection [265]. Following activation, JNK regulates apop-
tosis [120,256,265], enhanced expression of MMP [250], DNA damage [263], and DD 
[264]. The pro-apoptotic mechanisms of JNK seem to be associated with p53 induc-
tion [266] and with toll-like receptor 2 activation [265]. Although not yet investigated 
in the IVD, the interaction of JNK with miRNAs (e.g., miR-138, miR-133a-3p, miR-
133b-3p, miR-4268) is likely relevant [267–269]. Therefore, a better understanding of 
JNK signaling will be needed before its modulation can be effectively used as a ther-
apeutic means. 
NF-κB is described as the master regulator of inflammation. As it has become increas-
ingly clear that aberrant regulation of the NF-κB signaling pathway intervenes in DD, 
studies have started to investigate its potential clinical use of NF-κB-targeting therapies 
[270]. This signaling pathway is activated in response to damage, pathogens, and cellular 
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and mechanical stress and inflammation and regulates the expression of numerous genes 
related to inflammation, catabolism, and apoptosis/cell survival [241,271]. In mammals, it 
consists of a family of dimer-forming transcription factors that share the Rel homology, 
namely RelA (p65), c-Rel, RelB, p50, and p52 [272]. In the IVD, p65 expression and more 
importantly NF-κB activation are increased with degeneration [253,273], and pro-inflam-
matory cytokines, such as IL-1β and TNF-α, shown to activate NF-κB 
[241,250,253,273,274], are associated with painful DD [153,275]. Downstream targets of 
NF-κB include numerous matrix-degrading enzymes (MMP-1/-2/-3/-13, ADAMTS-4/-5), 
ECM proteins (asporin), inflammatory mediators (iNOS, COX-2, prostaglandin E), and 
chemokines (MCP-1), supporting the crucial role of this pathway in IVD and inflamma-
tion and degeneration [153,250,274–279]. In addition to specific NF-κB inhibitors such as 
ACHP (2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-(4-piperidinyl)-3-pyri-
dinecarbonitrile) or the NF-κB essential modulator (NEMO) binding domain peptide 
(NBD) [275,280], several natural drugs (e.g., curcumin [281], epigallocatechin gallate [255], 
or resveratrol [282]) have been described to modulate NF-κB activity. Furthermore, NF-
κB signaling can be altered by specific miRNAs (e.g., miR-150 [283]), but NF-κB activation 
can also affect expression of numerous miRNAs (e.g., miR-640 [284]). These findings offer 
new therapeutic approaches as miRNAs play a crucial relevance in IVD ECM degrada-
tion, cell apoptosis, and inflammation, e.g., due to their role as post-transcriptional regu-
lators [285]. 
Wnt/β-Catenin represents another therapeutic target in DD. It is a highly conserved 
pathway, involved in cell fate decisions during development, also regulating cell prolifer-
ation and tissue growth and maintenance [286]. Interestingly, Wnt signals are often only 
effective in localized areas between neighboring cells [287]. Activation of the Wnt/β-
Catenin pathway is initiated by binding of Wnt proteins to the so-called Frizzled receptors 
on the cell surface, which allows the transcriptional co-regulator β-catenin to shuttle to 
the nucleus, where it activates transcription of Wnt target genes [286,287]. Through mouse 
models, Wnt signal activity could be demonstrated during IVD development in the AF 
and the CEP [288], as well as early in life in the NP (likely associated with the postnatal 
rapid growth phase). In contrast, it was found to be downregulated with age [289] and 
DD [290,291], possibly through miR-532 [292]. Thus, activation of Wnt/β-Catenin may 
have the potential to reverse age-related degenerative changes in the IVD [289,290]. In 
fact, overexpression of Wnt in human herniated NP cells increased GAG release [293], 
supporting the possible therapeutic potential of the Wnt/β-Catenin pathway. However, 
Wnt/β-Catenin signaling was seen to induce senescence in IVD cells while also interacting 
with TNF-α in a positive-feedback mechanism, potentially contributing to disease pro-
gression [210,294]. Therefore, activation of Wnt/β-Catenin will only become therapeuti-
cally relevant when possible unwanted side effects are identified and controlled. 
As illustrated in Section 3.2, PI3/Akt is a well-known cell survival pathway and also 
regulates metabolism, proliferation, cell cycle progression, growth, and angiogenesis 
[295]. Due to its multifactorial role, PI3/Akt is tightly controlled, e.g., by its inhibitors as 
well as by cross talk with NF-kB [296–298]. The PI3/Akt pathway is primarily activated by 
cytokines [296] and GF [299–301] and is a critical player in DD [302]. GF activation, for 
example, resulted in Akt-dependent aggrecan accumulation in bovine NP cells [303] as 
well as reduced autophagy [302]. Akt has also been shown to positively regulate cell pro-
liferation [243] and counteract DD processes [300]. Natural drugs, such as epigallocatechin 
gallate and resveratrol, can activate PI3/Akt under stress conditions, thus stimulating im-
portant and therapeutically promising pro-survival mechanisms in IVD cells [304,305]. In 
line with that, inhibition of miR-4458 or miR-27a or stimulation of miR-21 may also have 
therapeutic benefits through PI3K/Akt modulation [306–308]. 
In addition, membrane receptors known to play a role in multifactorial disc cell reg-
ulation (see Section 3.1) are being investigated as therapeutic targets in DD. On the one 
hand, TRP channels have emerged as drug targets [134], due to correlations with pain 
intensity and duration [309]. On the other hand, toll-like receptors clearly hold promise 
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for the treatment of DD [164,310–312]. They are tightly associated with MAPK and NF-κB 
signaling and, thus, with inflammation and catabolism. One of the downstream targets of 
toll-like receptor 2 is NGF (nerve growth factor) [164], which plays a crucial role in IVD 
innervation and pain development. Thus, anti-NGF therapeutics may have the ability to 
manage pain in DD [167,185,313]. In this context, Link N, a naturally occurring peptide, 
could be of clinical relevance thanks to its inhibitory effect on NGF expression and to its 
regenerative capacity [314]. 
4.2. Growth Factor-Based Strategies 
A variety of GF have been studied for their capacity to encourage IVD regeneration, 
including PDGF, IGF-1, and FGF18, although the majority of GF that have been studied 
belong to the TGF superfamily [315]. Members of the bone morphogenetic protein (BMP) 
(mainly BMP2, BMP7) family and of the TGFβ (TGFβ1 and TGFβ3) subfamilies have been 
studied extensively, using in vivo models, to encourage anabolic activity in resident NP 
cells and counteract pathology [315,316]. In vivo testing of BMP has been mixed, with 
positive results shown for BMP2 and BMP7 in a small animal (rabbit) but negative results 
in a large animal (goat and canine) models [317,318]. More encouraging and more recent 
data have come from members of the growth differentiation factor (GDF) family (also part 
of the BMP family). GDF has been shown to have anabolic effects on IVD cells with GDF6 
(BMP13) also having potent chemoattractant properties for NP cells [319]. In vivo testing 
of GDF6 has shown positive effects in sheep, rat, and rabbit models with decreased signa-
tures of degeneration and evidence of disc tissue restoration [320,321]. GDF5 (BMP-14), 
due to promising preclinical studies [322], has been tested in two phase I/II clinical trials 
that are now complete [323]. Unfortunately, the placebo-controlled phase II trial failed to 
show efficacy; however, the patient sample size was small (N = 45). Although preliminary 
results of this type of potential treatment are promising, there are still challenges facing 
GF-based therapies. Firstly, they are inherently reliant upon the remaining degenerated 
disc cells to be healthy and sufficient in number to synthesize ECM and ultimately regen-
erate the disc tissue. Secondly, GF are often short-lived, limiting clinical use toward sus-
tained regeneration [324]; hence, recent works were investigating the use of microparticles 
as a GF delivery vehicle [325–327]. Arguably, this is a likely contributing factor to the lack 
of efficacy from the GDF5 clinical trial. Cell replacement therapy, on the other hand, cir-
cumvents both of these challenges. 
4.3. Cell Therapy-Based Strategies 
A wide range of potential cell-based therapies has been proposed for IVD regenera-
tive strategies, and there have been extensive reviews on the use of cellular therapies for 
regeneration of the IVD [328–331]. Cellular strategies have ranged from studies on termi-
nally differentiated chondrocytes [332–334] to more tissue-specific cell sources such as na-
tive disc cells from mature NP tissues [335–337] or immature notochordal cells from por-
cine discs [338,339]. There have been extensive studies using a number of stem cell 
sources, including MSC from bone marrow or adipose tissues [340]. More recent studies 
are exploring the potential of induced pluripotent stem cells in the treatment of DD [341–
347], and there are a number of ongoing clinical trials that use cellular injections into de-
generated IVD [348–351]. A number of recent reviews have been published proposing 
recommended routes to develop these therapies [93,352], which highlight important con-
siderations, particularly focused on the potential fate of cells injected into the harsh envi-
ronment of the degenerated discs [352–357]. The path to successful therapies is likely to 
combine cellular therapies with molecular targets (see Section 4.1), to inhibit the degener-
ated niche, together with biomaterial strategies to provide proper support for the cells 
during delivery. 
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4.4. Biomaterials and Nanotechnologies 
Biomaterials serve a fundamental role in tissue engineering (TE) by acting as scaf-
folds for in situ tissue replenishment as well as being carriers for cells and biological mol-
ecules. A number of review articles provide summaries of the numerous and varied bio-
materials suitable for the IVD [358–360]. Often, the biomechanics of the native tissue is 
replicated as closely as possible with the design of the biomaterial, along with the ability 
to encourage adherence, growth, and/or differentiation of cells. Since the IVD is composed 
of interconnected regions, each with different physical properties, the appropriate bio-
material for one region is generally different to the other. The NP demands most TE strat-
egies to employ the use of hydrogels as they are hydrophilic [361]. Conversely, biomateri-
als’ research for AF TE targets rather fibrous organized constructs, often achieved through 
electrospinning [362,363]. However, the natural complexity of the AF structure and com-
position is uniquely designed to resist an amazing variety of mechanical loads, both in 
nature and magnitude, which makes AF TE particularly challenging [363,364]. Indeed, 
integrated replacement strategies for the whole IVD are also commonly explored target-
ing both the NP and the AF, through highly hydrated composites [365–367]. Evidence has 
been predominantly collected in vitro/ex vivo, whereas in vivo studies comprise a far 
smaller proportion, which relates to the need for development of appropriate animal mod-
els previous to clinical trials. Remarkably, appropriate animal models to test disc regen-
eration strategies shall be conditioned by the existence of corresponding models for DD, 
which remains a challenge per se [368]. Evidence of this shortcoming comes from a 2014 
meta-analysis of in vivo and clinical studies for DD that reported only four clinical studies 
that utilized biomaterials [369]. Hence, continued progress is required in the field of IVD 
TE to increase translational research and the number of clinically approved biomaterial 
options for patients. Table 1 summarizes both key biomaterials and the related evidence 
that have been achieved for disc TE. 
Table 1. The major natural and synthetic biomaterials that have been studied for their potential use for treating interver-
tebral disc degeneration (DD). In the context of intervertebral disc (IVD) applications, potential strengths (+) and draw-
backs (−) for each material are provided as well as the IVD-specific studies accompanying them. 







 Injectable, biocompatible, tailorable 
properties, anionic properties at-
tract cationic PG [358]. 
 Diminishing structural integrity 
over time in calcium cross-linked 
hydrogels [370]. 
 In vitro/ex vivo: In situ gelation of calcium carbonate cross-
linked alginate hydrogel showing ability to maintain disc height 
over cyclic loading regime [371]. 
 In vitro: Porcine AF, NP, and transition zone cells were cultured 
in sodium chloride cross-linked alginate beads demonstrating 
IVD relevant ECM expression but diminished mechanical prop-
erties [370]. 
 In vitro: Bovine NP cells encapsulated in a photo-cross-linkable 
alginate hydrogel showed decrease cell viability over 14-d cul-
ture period [372]. 
Fibrin 
 Biocompatible, gelation time con-
trol, biodegradable, promotes ma-
trix synthesis stem cell-derived 
chondrocytes, non-immunogenic
[366]. 
 Soft in nature (however, can be 
modified to overcome this) [373]. 
 In vitro/ex vivo: Fibrin-genipin hydrogel with silk scaffold for 
AF and NP repair demonstrated cytotoxicity to cells in vitro and 
no recovery of disc height but matrix comparable to healthy disc 
in bovine organ culture [374]. 
 Ex vivo/in vivo: Fibrin-genipin adhesive hydrogel tested in bo-
vine organ culture and in a mouse model for AF defect repair 
demonstrating biocompatibility and biomechanics’ restoration 
[375]. 
 Clinical: A phase II, randomized, double-blind, placebo-con-
trolled study. Assessment of safety and preliminary efficacy of 
juvenile chondrocytes delivered using a fibrin carrier (NuQu®) 
for treating disc pain [376]. 




 Good cell adhesion, biocompatibil-
ity, and proliferation. Non-immu-
nogenic. Major component of IVD. 
 Poor mechanical properties with 
high degradation rate [361]. 
 In vitro: Dense collagen I hydrogel demonstrating comparable 
functional characteristics to NP [377]. 
 Ex vivo: Condensed collagen gel for NP replacement showed 
disc height restoration but extrusions of implant during stress 
testing [378].  
Composites: 
 In vitro: Human NP cells encapsulated type II collagen-hyalu-
ronic acid hydrogel crosslinked 1-ethyl-3 (3-dimethyl aminopro-
pyl) carbodiimide demonstrating cell proliferation but no in-
crease in matrix gene expression compared with control gel 
[379]. 
 In vivo: Transplantation of HA/collagen hydrogel into porcine 
nucleotomy model causing localized annular damage and in-
flammation [380]. 
Atelo-collagen 
 Low immunoreactivity, injectable 
due to liquid–solid transition when 
warmed to body temperature, sup-
port high-density cell cultures 
[360]. 
 Ex vivo: Autologous MSC encapsulated in atelocollagen II gel 
and transplanted into IVD of rabbit disc degeneration model re-
sulting in disc height recovery and PG accumulation [381].  
 In vivo: Autologous MSC encapsulated in atelocollagen II gel 
and injected into degeneration-induced NP of rabbits resulting 
in comparable PG accumulation to healthy control [382]. 
Chitosan 
 Supports IVD cell encapsulation, 
cationic properties retain PG, ther-
moresponsive [383]. 
 Cell adhesion and mechanical 
properties not ideal for IVD [358]. 
 In vitro: Bovine IVD cells encapsulated in chitosan hydrogel 
showed retention of NP-produced PG within gel. Gel cytotoxic 
towards AF cells [383]. 
 In vitro: Human MSC differentiation into NP-like cells in a chi-
tosan-glycerophosphate hydrogel [384].  
Gellan gum 
 Thermo-reversible gel properties, 
acid and heat resistant, non-cyto-
toxic, gelation without the need of 
harsh reagents, supports chondro-
cyte ECM deposition [360,385]. 
 Mechanically weak, requires high 
gelling temperatures, and lacks an-
chorage sites for adherent depend-
ent cells [386]. 
 In vitro: Ionic and photo-cross-linked methacrylated gellan gum 
showed lower water uptake ability but improved mechanical 
properties than gellan gum alone in the context of NP repair 
[385]. 
 In vitro/In vivo: Encapsulated MSC in gellan gum hydrogel 
show cell viability in vitro and signs of chondrogenesis in mouse 
subcutaneous implant [387]. 
 In vitro: Gellan gum hydrogels reinforced with nanocellulose 




 Retains water, non-immunogenic, 
anti-inflammatory, and low cost. 
Bioactive by binding with cell sur-
face receptors and ECM proteins,
which promotes cell infiltration 
[358]. 
 Osteogenic properties and cyto-
toxic at high concentrations [361]. 
 In vivo: MSC injected into rat IVD using 15% hyaluronic acid 
hydrogel. Initial significant cell loss followed by proliferation. 
An increase in disc height was shown [389]. 
 In vivo: Injection of hyaluronic acid hydrogel in rat tail disc de-
generation model demonstrating signs of pain marker reduction 
and attenuation of inflammation [390]. 
 Clinical: Prospective, multicenter, double-blinded, controlled 
phase 2 study. Safety and efficacy assessment of allogenic MSC 
injected with hyaluronic acid in disc degeneration patients (no 
results posted) [391]. 
Composites: 
 Ex vivo: Bovine NP cells cultured in a fibrinogen-hyaluronic 
acid-based hydrogel showed maintenance of some NP markers 










Laponite crosslinked pNIPAM-co-DMAc: 
 Thermo-responsive hydrogel in-
jectable above body temperature 
and solidifies upon cooling to 37 
degrees C. [393], supports differen-
tiation of human MSC into NP 
 In vitro: Assessment of hMSC to NP cell differentiation in 
pNIPAM hydrogel in normoxia and hypoxia [394]. 
 Ex vivo: Human MSC and bovine NPs encapsulated in pNIPAM 
hydrogel and injected into papain-induced bovine disc degener-
ation model [393]. 
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cells [394], excellent biocompatibil-
ity [395] 
 
 In vitro: Laponite cross-linked pNIPAM-co-DMAc encapsula-
tion of hMSC showed NP differentiation was not affected by cat-
abolic culture conditions [356]. 
 In vitro/ex vivo: HA-pNIPAM hydrogel seeded with autologous 
human NP cells and implanted in intact human IVD explant, 
demonstrating matrix synthesis [337]. 
HA-pNIPAM hydrogel:  
 Solidifies beyond 32 °C and is in-
jectable at room temperature [130] 
 In vitro/ex vivo: Improved NP-like differentiation of hMSC in 
vitro in HA-pNIPAM hydrogel with GF compared to alginate 
hydrogel. Direct implantation of hMSC/HA-pNIPAM into bo-
vine organ culture better than pre-differentiating hMSC [396]. 
 In vitro/ex vivo NP cell support and ECM deposition in HA-
pNIPAM hydrogel compared to alginate beads, in vitro. Im-
planted cell-hydrogel construct in bovine disc organ culture 




 Non-cytotoxic, easily synthesized, 
PEG-based hydrogels have high 
hydration properties. Photo-
polymerizable composites [358]. 
 Low biorecognition of cells, which 
affects cell adhesion properties, 
non-biodegradable [358].  
Composites: 
 In vitro: PEG-hyaluronic acid hydrogel screen for porcine AF 
and NP cell proliferation and sGAG production identified lower 
molecular weight hyaluronic acid gels were most suitable for the 
IVD [398]. 
 In vitro: Porcine NP cell 2D and 3D culture in photo-crosslinked 
PEG-laminin 111 hydrogel showed support of cell viability and 
matrix deposition [399].  
 In vitro/in vivo: PEG-albumin hydrogel tested with human 
disc cells by comparing 2D, 3D, and mouse subcutaneous im-
plant culture. Significantly higher SOX9 and HAS expression but 
not of aggrecan or collagen types I/II [400]. 
 Ex vivo: Injection of the photo-polymerizable PEG dimethacry-
late nano-fibrillated cellulose composite hydrogel into a bovine 
organ model of IVD resulting in disc height restoration [401]. 
 In vitro: Bovine NPs cultured in high-molecular-weight hyalu-
ronic acid cross-linked with PEG-amine showed reduced pro-in-
flammatory markers [402].  
Polyvinyl alcohol  
(PVA)-based hy-
drogels 
 Mechanical properties easily tailor-
able to IVD via PVA concentration 
adjustments [403,404]. 
 Non-degradable and expensive, 
limited biological testing for IVD 
applications [361]. 
 In vitro: PVA cryogel biomechanical testing found 3% PVA con-
centration with 3 freeze-thaw cycles was optimum for mimick-
ing compression properties of the NP [404]. 
 In vitro: Elastic modulus similar to native articular cartilage was 
attained from the fabrication of PVA and bacterial cellulose nan-
ofiber nanocomposite however, not directly compared to IVD 
biomechanical properties [405]. 
Composites: 
 In vitro: PVA containing laponite and bacterial cellulose nano-
composites were mechanically tested showing tailorable stiff-
ness. Wear and fatigue properties were enhanced with nanofiller 
adjustments and two-component PVA hydrogel could be tai-
lored to mimic IVD compression properties [406]. 
 Ex vivo: PVA-polyvinyl pyrrolidone composite hydrogel 
showed good fatigue properties and restored compressive stiff-
ness in human cadaver models [403]. 
 In vitro: PVA-silk composite cyrogel showing silk improved 
cell adhesion and survival of rabbit adipose stem cells over cul-
ture period. No proliferation was observed or capacity to en-




 Provide the advantages of natural 
and synthetic biomaterials while 
overcoming their individual disad-
 In vitro: Good cell viability of 3D cultured, de-differentiated hu-
man NP cells in FEFEFKFK SAPH. NP phenotype (except aggre-
can) and GAG synthesis was significantly higher at days 7 and 
14 compared to day 1 of 3D culture [413]. 
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vantages, easily tunable biome-
chanics via peptide sequence mod-
ifications, biodegradable and bio-
compatible, chemically defined, 
self-healing [408,409]. 
 Functionalization: Functionalize 
the peptide with motifs that repli-
cate useful biological molecules, 
e.g., BMP [410]. Graphene incorpo-
ration can act as delivery vehicles 
for biological factors [411]. Gra-
phene oxide is biocompatible and 
promotes cell adhesion [412]. 
 Stability and variable immuno-
genic concerns remain a challenge 
[408]. 
 In vitro: 3D culture of rabbit NP cells in KLD-12 SAPDH 
demonstrating increased cell viability and GAG release into me-
dia compared to hydrogel only control [414]. 
 In vitro: Rabbit NP cells showed greater cell viability, inward 
migration, and ECM synthesis in RLN functionalized RADA16 
compared with pure RADA16 [415]. 
 In vitro: Human degenerated NP cells 3D cultured in RKP 
(BMP7 motif) functionalized RAD16-I SAPH showed increased 
migration, proliferation, and expression of NP marker genes 
compared to RADA16-I alone [416]. 
 In vitro: Graphene oxide flakes incorporated into FEFEFKFK 
self-assembling peptide hydrogel mechanically similar to NP 
and supports bovine NP cells [417]. 







 Compressive and tensile strength, 
slow degradation, cytocompatible, 
modifiable with covalent attach-
ment of additional peptides [360]. 
 In vitro: Bovine AF cells seeded onto porous silk RGD-modified 
scaffolds demonstrating cell support and ECM deposition and 
higher collagen II and aggrecan expression than nonmodified 
scaffold [418]. 
 In vitro: Porcine AF and chondrocyte cells seeded onto biphasic 
silk scaffold for AF and fibrin/hyaluronic acid for the NP. In-
crease in GAG and collagen over four-week culture [419]. 
 In vitro/in vivo: Porcine AF cells and hMSC show cell viability 
and appropriate differentiation toward AF phenotype on multi-
layered silk scaffold compared to native AF cells. Subcutaneous 
mouse implant showed negligible immune response [420]. 
Alginate 
 Biocompatible, biodegradable, 
anti-microbial, cheap, high poros-
ity, support cell adhesion and 
growth [360]. 
 Poor native mechanical strength 
needs to be overcome with cross-
linking strategies [421]. 
Composites: 
 In vitro: Alginate-chitosan scaffold showed fiber alignment 
similar to AF and supports canine AF cell growth and ECM (col-
lagen, aggrecan) deposition [422]. 
 Human NP cells cultured on alginate scaffold demonstrated a 
fall in cell number over the 21-day culture period [423]. 
Atelo- collagen 
 Low-immunogenic derivative of 
collagen, safe and biocompatible, 
supports stem cell and disc cell re-
generation of the IVD [424].  
 In vitro: Rabbit NP cells seeded on atelocollagen types I and II 
scaffolds supplemented with BMP demonstrating anabolic gene 
and protein expression in type II but not type I scaffolds, com-
pared with control [424]. 
 In vivo: Rabbit AF cells cultured on atelocollagen honeycomb-
shaped scaffold and transplanted into rabbits showed cell pro-
liferation and production of hyaline-like cartilage [425]. 
Synthetic Polymers 
Type 




 Biocompatible, biodegradable, de-
composes to water and carbon di-
oxide and high biomechanical 
properties [358].  
 In vivo: PU mass transfer device transplanted into punctured 
porcine AF showed similar biomechanical properties to control 
group as well as enhanced energy production [426]. 
 Ex vivo: Implantation of biphasic PU scaffold into nucleotomy 
bovine whole organ culture model demonstrated restoration of 
disc height, cytocompatibility with native cells, and downregu-




 Biocompatible and biodegradable, 
approved by FDA for in-human use 
[358].  
 In vivo: Sheep AF cells seeded onto PLGA scaffold and im-
planted in mice demonstrating collagen I expression [429]. 






colic acid (PLGA) 
 Potentially encourages nerve in-
growth in the disc [428]. 
Composites: 
 In vitro: Human MSC cultured on a biphasic polyL-lactic acid 
nanofibrous outer scaffold and inner hyaluronic acid hydrogel 
to mimic the architecture of AF and NP, respectively. Increased 
IVD ECM protein accumulation in both regions over 28d culture 
period [430]. 
 In vivo: PLGA-fibrin gel plugs implanted into empty disc de-




 Supports adhesion, infiltration, and 
proliferation of MSC [431]. 
 Has been shown to encourage oste-
ogenic differentiation of MSC [431].
 In vitro: Human AF cells cultured within PDLLA/Bioglass® 
foam demonstrated proliferation over 4-week culture period 
and increased PG and collagen deposition than no Bioglass® 
foam control [432]. 
Composites: 
 In vitro: b-TCP and calcium carbonate particles loaded into 
acrylic-terminated oligo[D,L-lactide-co-(ε-caprolactone)]. Bio-
mechanical tests were performed, demonstrated that the addi-
tion of fillers aided achieving properties similar to the IVD [433]. 
Poly-ε-caprolac-
tone (PCL) 
 Biodegradable, FDA approved for 
in-human use, controlled decom-
position time through alternative 
polymer combinations, high elas-
ticity [358]. 
 In vitro: Electrospun PCL scaffold (AF) combined with cell-
seeded hydrogel for rat disc replacement showed effective cell 
infiltration [434]. 
 In vitro: Bovine MSC seeded onto nanofibrous anistropic PCL 
scaffold demonstrating collagen deposition and alignment com-
parable to native bovine AF [435]. 
 In vitro: PCL fibrous scaffold fabricated by wet-spinning 
showed rabbit AF cell adherence, proliferation, and increased 
collagen and aggrecan expression over 3-week culture [436].  
Microparticles (MP) are another type of biomaterial employed in IVD TE strategies. 
MP have long been explored within the pharmaceutical industry for use in drug delivery 
[437]. By tailoring their design, controlled temporal and dose release of biologicals can be 
achieved, e.g., to reach the biological targets reviewed in Section 4.1. Furthermore, con-
trolled administration of biologicals is extremely valuable for IVD TE, where cell and/or 
growth factor therapeutics would rely on single surgical procedures rather than on re-
peated delivery. In vitro, delivery of GDF6 through MP was demonstrated to be more 
efficient than repeated exogenous delivery to differentiate adipose stem cells into NP cells 
[327], which provides a promising direction for single surgical procedure approaches. MP 
have also been used to release the anti-inflammatory factor cyclooxygenase-2 in a canine 
dog model of DD [438], leading to encouraging results of preventing disease progression 
and reducing the inflammatory signature prostaglandin E2, a crucial nociception media-
tor. 
More recently, the advancements of nanomaterial technologies have lent themselves 
to IVD applications [439], allowing the tissue architecture to be replicated at a much finer 
scale than before, hopefully leading to biomaterials eventually indistinguishable from na-
tive tissue. Examples include poly L-lactic acid combined with nanofibrous scaffold to 
mimic the AF [430] and PGA-chitosan nanocomplex for NP regeneration [440]. Further-
more, nanomaterials are also being applied for growth factor delivery, such as assembling 
nanoparticles loaded with bFGF (basic fibroblast growth factor) onto microspheres for 
discogenic differentiation of MSC [441]. There is no doubt that the ever-advancing field of 
biomaterials will play a key role in providing solutions for DD in the future, whether that 
is supporting cell/drug delivery or acting purely as structural support for innate tissue 
regeneration. 
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5. Systems’ Modeling for the Exploration of IVD Degenerative and Regenerative 
Mechanisms 
Successful IVD treatment/regeneration strategies rely on a holistic understanding of 
the highly multifactorial (patho)physiological dynamics of the disc system, to be under-
stood at different time and length scales. In this sense, theoretical and computer modeling 
offers unique possibilities (Figure 3).  
 
Figure 3. In silico multiscale/integrative modeling as an objective in IVD research. (A) Organ level: 
3D finite element modelling. Deformable nonlinear geometry, heterogeneous assembly of tissues. 
(B) Tissue level: 3D finite element modelling. Composition-dependent multiphysics and aniso-
tropic behavior of the tissues, transport of solutes through tissue matrices. (C–D) Multicellular 
levels: agent-based modeling in regions of interest. Prediction of cell responses to multifactorial 
(micro-) environments. (E) Cell/subcellular levels: network modeling. Single cell stimulation, mul-
tiple states. 
For musculoskeletal joints commonly affected by highly prevalent disorders such as 
osteoarthritis, efforts in model developments have spanned over the scales, from the 
multibody musculoskeletal system to cell regulation networks, passing through detailed 
knee joint finite element models [442]. Even if the systematic integration of models of dif-
ferent nature at different scales is still incomplete, developments use to be much more 
modest as far as the IVD and DD are concerned. Indeed, model developments to simulate 
and virtually explore the pathophysiology of DD have long remained largely limited to 
the tissue and organ scales [443]. Only very recently, cell-scale models have finally 
emerged out of novel integrations of knowledge in IVD cell biology and computer meth-
ods in systems biology [35]. Arguably, the holistic modeling of the heterogenous IVD sys-
tem and the degeneration thereof is a tremendous challenge that will surely contribute to 
further progress in the development of in silico tools and medicine in other fields of rheu-
matology. 
On the one hand, the process of model construction and assessment against evi-
dences provides important clues about the minimum hypotheses and quantitative factors 
essential to reproduce known phenomena in health and disease. On the other hand, the 
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huge capacity for parametrical studies turns in silico models into unique virtual laborato-
ries to design new hypotheses and experiments. Eventually, model predictability, even in 
terms of relative analyses of simulation results, i.e., semiquantitative predictability, is de-
finitively cornerstone to enable mechanistic explicability and better control of patient 
stratification and treatment prognosis. Significant progress in IVD modeling has been 
made during the last years at multiple scales and is summarized below, along with rele-
vant findings about IVD regulation, DD, and possible therapies. 
5.1. Organ- and Tissue-Scale Simulations of the IVD Biophysical Regulation 
IVD tissues can be considered as biphasic materials, i.e., a combination of solid and 
liquid phases, at the millimetric scale. The porous solid phase corresponds to the tissue 
ECM, i.e., mostly collagen and PG. The liquid phase is mainly composed of water and 
solutes that flow through the pores of the solid phase. Biphasic mixture theory and Biot 
poroelastic theory allow to model IVD tissues and discriminate the respective roles of the 
solid and the fluid [444,445], especially in terms of mechanically coupled solute transport 
to the cells, for further simulations of cell activity [443]. The effect of mechanically coupled 
solute transport on cell activity has been referred to as indirect mechanotransduction, 
which depends on the capacity of the IVD tissues to deform [132] and control both the 
diffusion distances and the porosity, i.e., water content, in the disc [446]. Obviously, the 
whole process depends on tissue composition, i.e., on the effective condition of the IVD. 
Composition-based tissue models were developed for the articular cartilage [447] 
and were later applied to the IVD [448]. Implemented into detailed finite element models 
of the whole IVD, these models included the osmotic pressure in the disc tissues, con-
trolled by PG, collagen, and water contents as explicit model parameters. Strain energy 
density calculations in the AF further considered the anisotropy induced by the oriented 
collagen type I. Composition-dependent tissue modeling has paved the way to map the 
relative effects of local ECM depletion, in the NP, the AF, and the CEP, on the biphasic 
behavior of the IVD and on the indirect mechanotransduction phenomena [37,68]. Such 
tissue models were also coupled to phenomenological direct mechanotransduction theo-
ries, initially developed to predict the fate of bone MSC in endochondral bone healing, to 
calculate the likely long-term IVD remodeling after spine surgery [449]. The effect of PG 
and fixed-charge density contents on the diffusion of antibiotics from the vasculature to 
the IVD was also assessed through finite element mechano-transport simulations 
[450,451]. 
The hypothesis that impaired diffusion of metabolites across the IVD might acceler-
ate DD through cell nutritional stress [2,34] has motivated experimental measurements of 
cell viability in function of local pH and glucose concentrations in a diffusion chamber 
[207] and the establishment of empirical relationships between the oxygen, glucose, and 
lactate metabolism by IVD cells [98]. These works have been instrumental for the imple-
mentation of the aforementioned mechano-transport models, to couple IVD tissue me-
chanics, IVD morphology, local cell metabolism, and cell death [443]. Such simulations 
revealed that water contents in the disc, especially in the NP, largely control the effective 
diffusion of solutes, as well as the diffusion distances, under physiological mechanical 
loads [446,452]. 
The diffusion process in the disc ECM is relatively low and disc cell populations can 
withstand adverse nutritional environments during several hours to a few days before 
dying [207]. Accordingly, model simulations point out that the effect of molecule mech-
ano-transport on IVD cell activity becomes remarkable under sustained rather than under 
transient mechanical loads [446]. Furthermore, mechano-transport simulations suggested 
that indirect mechanotransduction on the long term, i.e., decades, might explain natural 
aging in the IVD [36]. Interestingly, a collection of patient-specific IVD models showed 
that large lumbar discs, i.e., higher than 14 mm, might be prone to spontaneous degener-
ation in contrast to average seize IVD, i.e., 8–12 mm high, because diffusion distances were 
too large to allow the nutrients to reach the cells in the center of the NP [453]. 
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Remarkably, models and simulations have proven great ability to identify specific 
risk factors and multifactorial mechanisms. Endplate obstruction because of sclerosis/cal-
cification has been long suspected to be responsible for nutritional disturbances in the IVD 
[454–456]. However, micro-modeling of vertebral endplate specimens coupled with full 
IVD finite element simulations suggests that the variability of the calcified endplate struc-
ture and porosity with aging and degeneration is unlikely to generate any barrier able 
induce nutritional stress in the IVD [457]. In contrast, the use of a composition-based IVD 
model showed that the early depletion of CEP in terms of PG and collagen type II in-
creases the overall permeability of the endplate, with a specially high influence of the loss 
of PG [37]. Such a permeability increase was also measured with aging [59], and simula-
tions indicated that it might provoke a chronic dehydration of the NP, down to water 
contents characteristic of Pfirrmann grade III degenerated discs, under daily physiological 
loads. This reduction of water largely reduced the capacity of the nutrients to reach NP 
cells located in the anterior part of the IVD, close to the AF. Interestingly, these results 
may provide mechanistic explanations of the severity of endplate-driven DD and LBP, as 
eventually revealed by Modic changes and vertebral endplate defects, in the general pop-
ulation [21,458,459]. Yet, such level of modeling cannot explain the pathophysiology of 
the CEP degeneration, per se, for which it is necessary to go down the scale. 
5.2. IVD Cell Models and Integration of Experimental Cell Stimulation Data 
As reflected through Sections 3 and 4, experimental studies at a cellular level in-
creased our understanding of anabolic or catabolic processes by IVD cells, and biochemi-
cal, metabolic, and mechanical stimuli that affect cell activity could be revealed. However, 
critical interactions within the multifactorial environment to which a cell is exposed over 
long periods of time are difficult to capture experimentally or clinically, pointing out the 
need for in silico approaches down to the cell level. 
Recently, a first agent-based modeling approach was proposed to simulate the be-
havior of NP cells in multicellular systems depending on biochemical microenvironments 
[35]. The model uses experimental findings to estimate cell viability and cell activity in 
terms of relative mRNA expressions of collagen types I and II and aggrecan and of MMP 
and ADAMTS proteins, based on user-defined nutritional factors and on inflammation. It 
exploited network modeling approaches from systems biology [460], to integrate the re-
spective effect of different micro-environmental cell cues on effective cell activities. It was 
then further developed to integrate direct mechanotransduction, i.e., load magnitude and 
frequency, effects [461]. On the one hand, such an approach informed about the likely 
differential behavior of non-inflamed and inflamed NP cells in similar microenviron-
ments. On the other hand, simulations captured the expected relative influence of differ-
ent mechanical load regimes on the capacity of NP cells to retain a full anabolic activity or 
provoke ECM depletion. 
Complex interactions at a (sub)cellular level can be approached through different 
modeling formalisms such as Boolean or Bayesian networks, Petri nets, constraint-based, 
rule-based, or agent-based models, differential equations, process algebra, interacting 
state machines, or cellular automata [462]. Still incipient in IVD research, models in sys-
tems biology often focus on one type of network, mainly metabolic-, signaling- and gene-
regulatory networks, facing limitations in interconnecting these networks toward holistic 
representations of cell simulations [462]. Future developments shall couple systems biol-
ogy approaches and organ/tissue-scale finite element models (Section 5.1). As such, the 
multiscale dynamics that control the IVD fate, and the mechanisms that lead to different 
phenotypes of IVD failure, will be represented, thereby allowing the mechanistic identifi-
cation of new therapeutical targets. Furthermore, integrating cell regulation pathways 
into single and collective cell behavior models could uniquely bridge the gap between 
IVD tissue phenotypes and the intracellular machinery to explain the apparent links with 
different genetic variants [57,463]. 
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5.3. Cell Signalling Pathway Models and Integration of Multi-Omics Data 
As exposed in Section 3, cell signaling (or signal transduction) is the process that de-
scribes how cells communicate with their environment and how they respond to external 
or internal stimuli [464]. Signal transduction pathways describe the transformation of a 
stimulus into a biochemical signal often starting with ligand-receptor binding, followed 
by an intracellular cascade of protein–protein interactions and resulting in a cellular re-
sponse/cell fate decision such as expression of a certain gene, apoptosis, proliferation, etc. 
Signal transduction plays a fundamental role in cellular behavior and the high complexity 
of cell signaling has led to many mathematical modeling approaches in order to better 
understand the underlying dynamics and deduce quantifiable conclusions [465]. In gen-
eral, signaling pathways can be described as node-edge graphs (directed or undirected) 
with the proteins as the nodes and the edges as the interactions between the proteins. 
These protein–protein interaction networks are stored in several publicly available data-
bases and aim to represent the existing knowledge of the scientific literature about either 
the entire interactome or the structure of specific pathways. Some of the popular databases 
are presented in Table 2, which can serve as a starting point for the creation of signal 
transduction pathways. 
Table 2. Publicly available databases on signaling pathways and protein–protein interactions. 
Title Content Size Address 
KEGG  
Integrated database resource consisting of 18 databases in-
cluding systems, genomic, chemical, and health information 
on the molecular interaction networks in biological systems 





Reactome Pathway database with interactive web visualization tool 





STRING Protein–protein interaction networks  
5000 organisms, 24.6 






Pathways of different species stored in wiki format 







Biological pathway data extracted from various databases 
with visualization tool 






Literature-curated mammalian signaling pathways from >50 
databases 






Database focused on interactions established by extracellular 







After extraction of the pathways of interest, prior-knowledge network (PKN) can be 
modeled with various mathematical approaches. The most widely used ones are either 
logic modeling employing Boolean or fuzzy-logic formalisms [473–475] or ordinary dif-
ferential equation models [476,477]. Whereas the former ignores time-dependent behavior 
and assumes instantaneous state changes of the system, the latter can describe transient 
behavior at a cost of a high number of reaction parameters that are difficult to identify 
experimentally. Interestingly, methodologies as presented by Mendoza and Xenarios 
[460] and Krumsiek et al. [478] use a generalized formulation to transfer discrete node-
edge graphs into continuous systems, to include dynamics into logic models. 
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Although considerable effort has been put to create databases on protein interaction 
and cell signaling pathways, the existing information has and will always have limita-
tions, e.g., biases (well-known proteins are studied more often than under-reported play-
ers), assumptions during the data mining algorithms, and ambivalent behavior of indi-
vidual protein pairs (stimulation and inhibition). The best approach to overcome this in-
trinsic limitation is to fit the PKN structure to our own experimental data. On this front, 
various massive parallel sequencing platforms can be used to provide systematic molec-
ular profiling of human cells, which will be tackled in the next few years by the European 
Innovative Training Network Disc4All in IVD research [479]. The technologies are sum-
marized under the term ‘omics, considering, e.g., genomics, proteomics, metabolomics, 
lipidomics, and other high-throughput technologies [480]. 
An attractive techniques allowing protein detection with high sensitivity and speci-
ficity as well as relatively simple experimental protocols are multiplexed ELISA immuno-
assays on magnetic beads [481]. This technique allows the simultaneous measurement of 
phosphoprotein activity and cytokine abundance (several dozens in one sample) after 
stimulation of biological samples [482]. This high-dimensional data serves as a starting 
point to optimize and fit the developed signaling pathway models. Here, either genetic 
algorithms [483] or integer linear programming formulations [484] are viable approaches 
to systematically fit node-edge graphs to the experimental data. In particular, the 
CellNOpt [485] and SigNetTrainer that is part of the CellNetAnalyzer toolbox [486] offer 
user-friendly ways to perform such optimization routines. A recently developed alterna-
tive is DoRoTHea [487] that creates signal transduction graphs based on gene expression 
measurements taken, for example, from microarray studies. In the end, these pathways 
models can be used to investigate the overall dynamics of the system, identify the most 
influential nodes, or focus on the specific parts of the signal transduction network to see 
the effect of various stimuli and/or knockouts [465]. 
Many pathways are involved in IVD cell regulation [187] and their individual analy-
sis has been performed in the past in a vast amount of studies [488–491]. Until now a 
holistic representation of pathways in the IVD is still missing and a possible approach to 
tackle this obstacle might follow the strategy described above, as proposed in the Disc4All 
project [479]. Especially, the requirement of high-quality experimental data (ideally from 
relevant in vitro models) is one of the major challenges, in order to capture the mecha-
nisms of multifactorial diseases such as DD. However, the falling costs of high-through-
put technologies will lead to increasing amounts of publicly available molecular infor-
mation. The rapid developments in computational biology tools might then bridge the 
gap between information and mechanistic knowledge in DD and IVD regenerative thera-
pies. 
6. Conclusions 
This review provides an integrative view of the current knowledge about the non-
degenerated and degenerated IVD at the tissue, cell, and molecular levels and of current 
disc regeneration strategies. It further summarizes recent modeling approaches that illus-
trate the capacity of in silico models to simulate complex interactions over different time 
and length scales and supports improved identification of risk factors and the effect 
thereof at the molecular level, for improved targeted therapies. 
At the tissue level, sophisticated interactions among PG, water, and different types 
of collagen are crucial to keep the IVD mechanically competent, also ensuring proper cues 
at the cell level for optimal tissue maintenance, regardless of the harsh mechanical, osmo-
lar, metabolic, and pH environments. Despite the highly elaborated responses of IVD cells 
to their adverse microenvironment, IVD homeostasis is fragile, and multifactorial pertur-
bations of cellular cues might trigger a cascade of catabolic responses, such as increased 
synthesis of catabolic cytokines, matrix-degrading enzymes, or neurotropic and angio-
genic factors, which gradually affects ECM integrity. 
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Those responses are triggered by complex and interconnected cell signaling path-
ways, the detail of which becomes better known, based on multiple controlled experi-
ments that exploit gene-editing techniques, among others. Such understanding is of ut-
most importance to develop new molecular treatments and is being exploited in regener-
ative strategies based on pharmacological solutions. The challenge resides, however, in 
the proper anticipation and control of the differential expression of the pathways and 
cross talks, when the IVD cells are subjected to complex cocktails of stimuli, part of which 
depend on top-down mechanical, nutritional, and chemical spatiotemporal events. 
Cellular therapies for IVD regeneration have been widely studied with several po-
tential cell sources investigated. However, given the harsh conditions within a degener-
ated IVD and the need to control mechanotransduction effects, combined cell therapy, 
molecular targets, and biomaterials approaches shall be the most promising approaches. 
Because of the complexity to thoroughly apprehend the effect of such combinations, ho-
listic understanding of top-down and bottom-up propagations of the consequences of 
(non-)altered cell activities shall be necessary. 
In silico modeling approaches were shown to have great potential to simulate multi-
factorial mechanisms and identify the effect, down to the cell level, of specific risk factors 
across the scales. These approaches are still relatively recent and even incipient (e.g., at 
the molecular and cell scales) in IVD research. Yet, ongoing studies are providing robust 
proofs of concepts of the exploitability of computer models and simulations and open new 
horizons in IVD science, by simulating multicellular systems through network- and agent-
based modeling. The control of these calculations from the tissue and organ scales can be 
described through multiphysics and finite element modeling. Latest explorations in this 
sense targeted mechanotransport and indirect mechanotransduction phenomena and re-
sults pointed out the importance of different spatio-temporal events that involve the entire 
IVD. Eventually, models and simulations can stand for virtual labs, thereby allowing us 
to virtually test numerous regeneration approaches that will be difficult to anticipate or 
extremely costly otherwise. 
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ADAMTS A disintegrin and metalloproteinase with thrombospondin motifs 
AF Annulus fibrosus 
BMP Bone morphogenetic protein 
CEP Cartilage edplate 
DD IVD degeneration 
ECM Extracellular matrix 
ER Endoplasmatic recticulum 
ERK Extracellular signal-regulated kinase 
FA Focal adhesion 
FGF Fibroblast growth factor 
GAG Glycosaminoglycan 
GDF Growth differentiation factor 
GF Growth factor 
HIF Hypoxia inducible factor 
IGF Insulin-like growth factor 
IL Interleukin 
IVD Intervertebral disc 
JNK c-Jun NH2terminal kinase 
LBP Low back pain 
MAPK Mitogen-activated protein kinase 
MMP Metalloproteinase 
MP Microparticle 
MSC Mesenchymal stromal cell 
mTOR Mammalian target of rapamycin 
NF-κB Nuclear factor kappa B 
NGF Nerve growth factor 
NP Nucleus pulposus 
p38 p38 MAPK 
PCL Poly-ε-caprolactone 
PDGF Platelet-derived growth factor 
PDLLA Poly D,L-lactide 
PEG Polyethylene glycol 
PG Proteoglycan 
PGA Polyglycolic acid 
PKN Prior-knowledge-network 
PLGA Polylactic-co-glycolic acid 
PNIPAM Poly N-isopropylacrylamide 
PU Polyurethane 
TE Tissue engineering 
TGF Transforming growth factor 
TNF-α Tumor necrosis factor alpha 
TonEBP Tonicity-responsive enhancer binding protein 
TonEBP/NFAT5 
Tonicity-responsive enhancer binding protein/nuclear factor of activated T-
cells 5 
TRP Transient receptor potential 
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